IDXX · IDEXX Laboratories, Inc.
$569.552026-05-17Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$299
-47.5% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($223 · $329) Analysts Range ($730 · $830) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $3.2B | — | 30.8% | 17.5% | $818MM | −$381MM | $437MM | 11.7% | — | 42.5% | $1.9B | $9.23 | — |
| 2022.Q4 | $3.4B | 4.7% | 28.4% | 21.0% | $755MM | −$444MM | $310MM | 11.7% | — | 33.7% | $2.5B | $8.42 | — |
| 2023.Q4 | $3.7B | 8.7% | 31.9% | 20.4% | $929MM | −$156MM | $772MM | 11.3% | — | 36.7% | $2.5B | $10.47 | — |
| 2024.Q4 | $3.9B | 6.5% | 30.8% | 20.0% | $960MM | −$286MM | $674MM | 11.9% | — | 36.2% | $2.8B | $11.01 | — |
| 2025.Q4 | $4.3B | 10.4% | 33.6% | 20.0% | $1.2B | −$155MM | $1.0B | 12.1% | — | 39.5% | $3.1B | $13.13 | 31.8 |
| italics below = DCF projection · 10yr Rev CAGR: 9% |
| 2026.Q4 | $4.7B | +8.8% | 33.7% | 20.0% | $1.3B | −$244MM | $1.0B | 10.0% | $927MM | 39.5% | $3.3B | $14.73 | 38.7 |
| 2027.Q4 | $5.1B | +8.7% | 33.7% | 20.0% | $1.4B | −$271MM | $1.1B | 9.9% | $912MM | 39.7% | $3.6B | $16.01 | 35.6 |
| 2028.Q4 | $5.6B | +9.7% | 33.7% | 20.0% | $1.5B | −$340MM | $1.2B | 9.7% | $879MM | 40.0% | $3.9B | $17.56 | 32.4 |
| 2029.Q4 | $6.2B | +10.5% | 33.7% | 20.0% | $1.7B | −$348MM | $1.3B | 9.6% | $905MM | 40.5% | $4.3B | $19.40 | 29.4 |
| 2030.Q4 | $7.0B | +13.6% | 33.7% | 20.0% | $1.9B | −$519MM | $1.4B | 9.5% | $861MM | 41.6% | $4.8B | $22.02 | 25.9 |
|
| Term. Yr+ | $10.6B | 4.1% | 24.7% | 20.0% | $2.1B | −$365MM | $1.7B | 8.6% | $15.7B | 23.6% | — | — | — |
Active scenario IV: $299 (-47.5% vs market)